🫀 Cardiogenic Shock Survival: Impella’s Decade-Long Edge
Dr. Baliga's 'Podkasts for Curious Docs'
🚨 Cardiogenic Shock—A Decade Later The DanGer Shock Trial shows that patients with STEMI and shock treated with the Impella CP microaxial flow pump lived 600 more days over 10 years vs standard care alone. 📉 Mortality: 52.5% vs 68.8% (HR 0.70) 🛠️ Despite higher adverse events, the survival benefit endured a full decade. 📊 This changes how we think about long-term outcomes in mechanical support. 🔗 Time to revisit your shock protocols? #DanGerShock #Impella #CardiogenicShock #STEMI #LongTermOutcomes #NEJM #MCS #Cardiology #SurvivalBenefit #ImpellaCP
info_outline
💓 Genes, Gradients, and Game-Changers: FAQs on Hypertrophic Cardiomyopathy
Dr. Baliga's 'Podkasts for Curious Docs'
🧠 Hypertrophic Cardiomyopathy — A Masterclass from Eugene Braunwald 🧬 📌 Just published in NEJM (Aug 2025): a sweeping, state-of-the-art review on HCM — from Teare’s first autopsy to myosin inhibitors, AI diagnostics, and gene therapy. 💥 Clinical insights, historical depth, trial data (EXPLORER-HCM, SEQUOIA-HCM, VALOR-HCM), and future-facing advances—all distilled into one must-read. 📉 SCD prevention, 🫀 LVOT obstruction, 🧪 MYBPC3/MYH7 mutations, 🧬 proteomics, and more. 🔗 Essential reading for cardiologists, geneticists, and...
info_outline
🔬 Silence APOC3, Slash Triglycerides, A New Era in Triglyceride Control
Dr. Baliga's 'Podkasts for Curious Docs'
🚨 New NEJM Study on Olezarsen 🚨 In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! 📉💥 ✅ Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol ✅ No rise in LDL-C ✅ Well-tolerated with mild injection-site reactions 🔬 APOC3 inhibition emerges as a game-changer in lipidology. 📖 ESSENCE–TIMI 73b Trial | Funded by Ionis Pharmaceuticals #Cardiology #LipidLowering #PrecisionMedicine #NEJM #Olezarsen #TGlowering #CVRisk #TIMI...
info_outline
Dr RR Baliga's Philosophical Discourses: Dogen (Japan, 1200–1253 CE) – Founder of Soto Zen
Dr. Baliga's 'Podkasts for Curious Docs'
🌸 Dōgen Zenji (1200–1253), founder of the Sōtō Zen school in Japan, taught that true practice lies in zazen—“just sitting” 🧘♂️—where enlightenment and practice are inseparable. His Shōbōgenzō continues to inspire mindfulness & presence today. ⏳✨ #Zen #Mindfulness
info_outline
NSTEMI: 📉 Less Ischemia, Less Reintervention
Dr. Baliga's 'Podkasts for Curious Docs'
🚨 New Evidence in NSTEMI Care! 🫀 The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI. 🎯 Key win? Fewer revascularizations, better outcomes — physiology beats anatomy again. 📚 Published in JAMA, presented at #ESC2025 🔗 Read more: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.16189 #Cardiology #NSTEMI #FFR #InterventionalCardiology #EvidenceBasedMedicine #SLIMTrial
info_outline
Real-World Rx 💊, Real Results 📉: GLP-1 Agents Slash HFpEF Risk
Dr. Baliga's 'Podkasts for Curious Docs'
💥 Practice-Changing Evidence in HFpEF! 💥 In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉 ⚖️ No meaningful difference between the two agents. 🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies’ expanding role in cardiometabolic HFpEF 🫀 #Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure
info_outline
The AMALFI AF Screening Trial-📈 Atrial Fibrillation Unmasked: A Modest Win for Mailed Monitors
Dr. Baliga's 'Podkasts for Curious Docs'
📢 Just read the #AMALFI trial in JAMA 📰 — a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk 📦🫀. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use 💊🧠. Stroke rates were similar ⚖️. 🎯 Key takeaway: Remote, mail-based AF screening is feasible and nudges diagnosis rates — but will it move the needle on outcomes? #AFib #StrokePrevention #RemoteMonitoring #ECG #Cardiology #RCT #JAMA #DigitalHealth #Geriatrics 🧓📉
info_outline
🛑 AFib Gone, OAC Gone? ALONE-AF Challenges Lifelong Therapy
Dr. Baliga's 'Podkasts for Curious Docs'
🚨 New Trial Alert 🚨 Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial 🫀 suggests yes—in selected patients with no AF recurrence, stopping DOACs reduced major bleeding 🌟 without increasing stroke risk 🧠. 📉 0.3% vs 2.2% for the composite outcome (P = .02) 📍 Carefully monitored, low-risk patients may benefit most. 📝 Editorial: Recommends shared decision-making 🤝 & individualized rhythm monitoring. 📚 A potential shift in post-ablation care. 🔗 #AFib #Anticoagulation #EPTrials #CardioTwitter #StrokePrevention #JAMA...
info_outline
🦠💔Bugged After the Heartbreak? Does H. pylori Screening After MI Prevent GI Bleeds?
Dr. Baliga's 'Podkasts for Curious Docs'
🚨 New Findings from the HELP-MI Trial! 🇸🇪🧪 Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)? 💉 Over 18,000 patients across 35 Swedish hospitals 📉 Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) 🔍 BUT: Clear benefit in patients with anemia (RR 0.44–0.64) and chronic kidney disease (RR 0.75) 🧠 Key Takeaway: Routine screening isn’t broadly warranted—but targeted testing in high-risk AMI patients may be the smarter path forward. 📊...
info_outline
🧬 Risk, Recurrence, Relief: Apixaban’s Edge in VTE 🌡️ Emphasizes the risk stratification, recurrence data, and therapeutic benefit
Dr. Baliga's 'Podkasts for Curious Docs'
🩺 New Insights on Apixaban for VTE! 📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE. 📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding. 🎯 Editorial in NEJM urges a shift from binary labels (“provoked vs unprovoked”) to a patient-centered, risk-adapted approach. 🧠 Art meets evidence in the decision to extend anticoagulation. 💬 Let’s rethink how we label, risk-stratify, and treat. 📚 #VTE #Apixaban #Anticoagulation #NEJM #HI_PRO #Thrombosis #PrecisionMedicine...
info_outlineSiddhartha Gautama, known as the Buddha (“the awakened one”), was a spiritual teacher who founded Buddhism in the 5th or 6th century BCE in South Asia.
His core teachings include the Middle Way, the Four Noble Truths, and the Noble Eightfold Path, emphasizing mindfulness, ethics, and liberation from suffering.